Myocardial production and release of MCP-1 and SDF-1 following myocardial infarction: differences between mice and man by Boyle, Andrew J et al.
RESEARCH Open Access
Myocardial production and release of MCP-1 and
SDF-1 following myocardial infarction: differences
between mice and man
Andrew J Boyle
1*, Yerem Yeghiazarians
1, Henry Shih
1, Joy Hwang
1, Jianqin Ye
1, Rich Sievers
1, Daiwei Zheng
1,
Jath Palasubramaniam
2, Dharshan Palasubramaniam
2, Connie Karschimkus
2, Robert Whitbourn
2, Alicia Jenkins
2
and Andrew M Wilson
2
Abstract
Background: Stem cell homing to the heart is mediated by the release of chemo-attractant cytokines. Stromal
derived factor -1 alpha (SDF-1a) and monocyte chemotactic factor 1(MCP-1) are detectable in peripheral blood
after myocardial infarction (MI). It remains unknown if they are produced by, and released from, the heart in order
to attract stem cells to repair the damaged myocardium.
Methods: Murine hearts were studied for expression of MCP-1 and SDF-1a at day 3 and day 28 following
myocardial infarction to determine whether production is increased following MI. In addition, we studied the
coronary artery and coronary sinus (venous) blood from patients with normal coronary arteries, stable coronary
artery disease (CAD), unstable angina and MI to determine whether these cytokines are released from the heart
into the systemic circulation following MI.
Results: Both MCP-1 and SDF-1a are constitutively produced and released by the heart. MCP-1 mRNA is
upregulated following murine experimental MI, but SDF-1a is suppressed. There is less release of SDF-1a into the
systemic circulation in patients with all stages of CAD including MI, mimicking the animal model. However MCP-1
release from the human heart following MI is also suppressed, which is the exact opposite of the animal model.
Conclusions: SDF-1a and MCP-1 release from the human heart are suppressed following MI. In the case of SDF-1a,
the animal model appropriately reflects the human situation. However, for MCP-1 the animal model is the exact
opposite of the human condition. Human observational studies like this one are paramount in guiding translation
from experimental studies to clinical trials.
Background
The adult mammalian heart has limited capacity for
self-repair. Enhancing the heart’s own reparative
mechanisms represents an attractive therapeutic option
for patients who have suffered myocardial infarction
(MI). Stem cell chemo-attractant cytokines are thought
to be released from the heart in response to injury, in
an attempt to stimulate endogenous tissue repair path-
ways. Monocyte chemotactic protein-1 (MCP-1, CCL2)
and stromal-derived factor 1 alpha (SDF-1a, CXCL12)
are two stem cell chemo-attractant cytokines that are
thought to play a role in post-infarct cardiac repair.
SDF-1a is constitutively expressed by many tissues,
including the heart [1]. Following MI, cardiac SDF-1a is
thought to contribute to a stem cell cytokine gradient
that causes homing of stem cells to the heart [2,3]. For
this to occur, SDF-1a must be produced in the heart
and released into the circulation. Experimental models
have yielded conflicting data about cardiac expression of
SDF-1a, with some finding increased expression after
MI [2,4-6] and others finding decreased expression [1,7].
Furthermore, the data concerning serum levels of circu-
lating SDF-1a are also conflicting. In patients, some stu-
dies find increased levels after MI [8,9], while others
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serum level of SDF-1a is actually reduced [2], whereas
in the canine model it is increased [1]. Thus, whether
SDF-1a is released from the heart to create a cytokine
gradient following MI remains unknown.
The role of MCP-1 in post-infarction left ventricular
(LV) remodeling is complex. MCP-1 has been implicated
in numerous steps along the way to post-infarction heart
failure: in the development of atherosclerosis [11], in
atherosclerotic plaque instability [12], in recruitment of
monocytes to the heart following MI [13] and in post-
infarction LV remodeling [14]. In experimental animal
models, MCP-1 is also chemoattractant for stem cells
[15,16]. MCP-1 levels are increased in peripheral blood
following MI, both in rats [17] and in patients [18-20] and
these levels correlate with prognosis [21]. It has been
assumed that these peripheral blood levels are reflective of
cardiac release causing a chemo-attractant cytokine gradi-
ent towards the heart. Thus modulation of the MCP-1/
CCR2 axis has been proposed as a novel therapeutic target
to treat post-infarction LV remodeling [14,21].
It is not clear whether the serum levels of these cyto-
kines after MI is reflective of cardiac production and
release, or whether they are coming from other tissues.
Before clinical trials utilizing these cytokines as potential
therapeutic agents are undertaken, these questions must
be addressed. We therefore have studied the murine and
human patterns of myocardial production and release of
these cytokines in response to MI.
Methods
Animal study
Male C57BL/6J were used for all murine experiments.
Animals were handled according to the guidelines of the
Institutional Animal Care and Use Committee at the
University of California San Francisco.
Myocardial infarction
MIs were induced surgically by a permanent ligation of
the left anterior descending (LAD) coronary artery as
previously described [22]. Briefly, after intubation and
ventilation, thoracotomy is performed and permanent
ligation of the LAD is made by a 7-0 suture in the ante-
rior myocardium at 50% of the length of the heart from
the anterior-inferior edge of the left atrium to the apex.
Tissue preparation and analysis
Animals were humanely sacrificed under general
anesthesia. Baseline non-infarcted animals (n = 3) were
compared with post-infarct animals at 2 time-points fol-
lowing MI: early (day 3; n = 3) and late (day 28; n = 3).
Hearts were arrested in diastole with injection of con-
centrated KCl and the hearts immediately removed. For
RNA analysis, the left ventricle was dissected away from
the rest of the heart, divided into infarct, border and
remote zones, and rapidly frozen by immersion in liquid
nitrogen. Total RNA was isolated from left ventricles by
TRIzol reagent (Invitrogen). Trace genomic DNA in
total RNA was removed by Dnase I and Rneasy Mini
Kit (Qiagen). cDNA was generated from 0.1 mg of total
RNA by using SuperScript III First-Strand Synthesis kit
(Invitrogen). Microarrays were performed using Affyme-
trix 1.0 Mouse gene chip. Data were normalized using
robust multi-array average (RMA) method. Control and
low performing probesets (those with intensity values
below a threshold across all samples, the threshold was
taken to be the global lowest 25
th percentile of intensity
values) were excluded from analysis. Also, based on
Affymetrix’s annotation information, only those probe-
sets which were part of the main design of the array
and perfectly matching only one sequence were consid-
ered for analysis of differential expression. 20648 out of
35557 probesets remained after filtering
Human Study
The human clinical study was approved by the Human
Research Ethics Committee at St Vincent’s Hospital Mel-
bourne Australia. Patients undergoing cardiac catheteri-
zation or cardiac surgery gave written informed consent
for blood samples to be taken from the coronary artery/
aortic root and coronary sinus. For the cardiac catheteri-
zation patients, blood was taken from the coronary artery
ostium via the cardiac catheter used for the case. A
catheter was placed into the coronary sinus under fluoro-
scopic guidance and a sample was taken from the sinus
at the same time. For the cardiac surgery patients, during
cannulation of the heart in preparation for bypass, blood
samples were taken from the coronary sinus (retrograde
cardioplegia catheter) and from the aortic root (aortic
bypass cannula). Importantly, in order to eliminate white
blood cell activation from the bypass pump confounding
our results, samples were taken before initiation of cardi-
opulmonary bypass and the blood had not entered the
pump circuit. The blood was separated into serum and
plasma and stored at -80 degrees C. For cytokine levels,
ELISA was performed using antibodies to MCP-1 and
SDF-1a R and D systems, Minneapolis MN) according to
the manufacturer’s protocol. The degree of coronary
artery disease was assessed by an experienced cardiologist
who was blinded to the results of the serum analysis.
Patients were placed into categories depending on the
degree of coronary artery disease, the clinical presenta-
tion and the results of serum cardiac enzymes and elec-
trocardiogram (ECG). Patients were then described as
angiographically normal coronary arteries, stable coron-
ary artery disease, unstable angina and acute MI.
Statistical analysis
For murine mRNA studies, moderated t-statistics (as
implemented in the limma package in R/Bioconductor)
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The theoretical (raw) p-values were then adjusted for
multiple testing by controlling the false discovery rate
(FDR). A cut-off of 0.05 was used on the FDR adjusted
p-values to declare a probeset to be significant. For
human studies, data are presented as mean ± SD
unless otherwise stated. Cytokine levels are compared
between groups using ANOVA with post hoc Fishers
test. Patient demographics were compared using one-
way ANOVA with Bonferroni post-hoc correction for
continuous variables (age), and Pearson’sC h i - s q u a r e
for comparison of categorical variables for other
demographic data. A p-value of 0.05 or less is consid-
ered significant.
Results
Myocardial Production and Release of SDF-1a are Similar
in Murine and Human Myocardial Infarction Respectively
In the adult mammalian heart, mRNA encoding for
SDF-1a and its cognate receptor CXCR4 are detectable
at baseline. Following myocardial infarction, the consti-
tutive expression of SDF-1a mRNA is reduced by
approximately 25% at day 3, and this persists out to day
28 in all regions of the heart (Figure 1A). The
Figure 1 SDF-1a expression in the murine heart. There is reduced expression of mRNA for SDF-1a (A) in all regions of the murine heart
following myocardial infarction. This occurs early, and remains suppressed for 28 days. There is no change in mRNA for its receptor CXCR4 (B).
(C) Myocardial protein levels of SDF-1a are also reduced following MI. IZ = infarct zone; BZ = border zone of the infarct; RZ = remote zone. n =
3 for each region at each time-point.
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unchanged in any region of the heart at either time-
point following MI (Figure 1B). Similarly, the protein
level of SDF-1a is reduced following MI (Figure 1C).
In humans, SDF-1a is constitutively released from the
heart into the circulation at baseline, resulting in a posi-
tive gradient from the coronary artery to the coronary
s i n u s( T a b l e1 ,F i g u r e2 )a n dt h i sr e l e a s ei ss u p p r e s s e d
after MI. Furthermore, SDF-1a release is also abolished
in stable coronary artery disease and in unstable angina,
suggesting that the presence of coronary artery disease,
rather than the myocardial damage during MI, is
responsible for the reduction in cardiac release of SDF-
1a. The changes in cardiac production and release of
SDF-1a in response to MI appear to be similar in the
mouse and human.
Myocardial Production and Release of MCP-1 Differ
Between Murine and Human Myocardial Infarction
At 3 days after MI, MCP1 mRNA increases 4-6 fold in
all regions of the heart, and returns toward baseline by
day 28 (Figure 3A). This time-dependent rise in the
expression of the ligand is mirrored by its receptor
CCR2 (Figure 3B). The protein level of MCP-1 is not
increased in mice following MI (Figure 3C).
In humans, MCP-1 is constitutively released from the
heart at baseline (Table 1). However, in direct contrast
to the murine model, MCP-1 release from the heart is
suppressed following myocardial infarction (Figure 4,
Table 1). Furthermore, MCP-1 release is suppressed in
stable CAD and unstable angina to similar degrees as
following MI, suggesting that the presence of coronary
artery disease, rather than the myocardial damage dur-
ing MI, is responsible for the reduction in cardiac
release of MCP-1. The changes in cardiac production
and release of MCP-1 in response to MI appear to be
the opposite in the mouse and human.
Infarct Size Does Not Affect Human Myocardial Cytokine
Release
Transmyocardial gradient of MCP-1 and SDF-1a had no
correlation with infarct size, as determined by peak tro-
ponin-I (TnI) level or peak creatinine kinase (CK) level.
Pearson’s correlation r-value between TnI and MCP-1
was 0.02 (p = 0.95) and between TnI and SDF-1a was
0.31 (p = 0.30); between peak CK and MCP-1 was -0.06
(p = 0.88) and between CK and SDF-1a was 0.31 (p =
0.38).
Influence of Timing and Patient Demographics After MI
To ensure that the time post-MI that the samples were
taken did not influence our results, we plotted the
trans-myocardial gradients of SDF-1a and MCP-1 versus
time from the MI. The trans-myocardial gradients of
SDF-1a and MCP-1 were not related to the time mea-
sured after MI (Figure 5). Furthermore, the patients’
age, risk factors and medications were no different
between groups. There was, however, a significantly
higher percentage of males in the coronary artery dis-
ease groups compared to the normal controls (Table 2).
Discussion
This study has several important novel findings. Firstly,
myocardial release of SDF-1a into the circulation is
decreased in humans following MI and in all stages of
coronary artery disease. Secondly, myocardial release of
MCP-1 is also suppressed in patients post-MI and in
the presence of coronary artery disease. Thirdly, and
perhaps most importantly, the human release pattern of
cytokines sometimes reflects the pattern seen in rodent
Table 1 Cytokine Levels in Patients With Coronary Artery
Disease
Coronary Artery Coronary Sinus Gradient
MCP1
Normal 94.6 ± 54.1 146.7 ± 56.3 52.1 ± 24.3
Stable CAD 104.9 ± 46.7 116.7 ± 52.2 11.7 ± 21.9 *
UAP 65.3 ± 27.5 79.4 ± 18.4 * 14.1 ± 12.2 *
MI 87.8 ± 41.4 101.9 ± 38.2 * 12.5 ± 28.4 *
SDF-1a
Normal 1982.0 ± 608.1 2648.3 ± 896.3 666.3 ± 288.1
Stable CAD 2570.8 ± 694.4 2544.3 ± 710.8 -26.4 ± 377.7 *
UAP 1694.0 ± 321.6 1404.0 ± 444.2 * -290.0 ± 244.8 *
MI 1705.4 ± 298.3 1592.4 ± 350.4 * -113.0 ± 325.6 *
* p < 0.05 vs Normal. CAD = coronary artery disease; UAP = unstable angina
pectoris; MI = myocardial infarction.
Figure 2 SDF-1a release from the human heart. In humans, SDF-
1a is constitutively released from hearts with normal coronary
arteries. However, following MI, myocardial release of SDF-1a is
reduced. This is consistent with the murine mRNA expression
pattern. SDF-1a release is suppressed in all stages of coronary artery
disease, suggesting that coronary artery disease, rather than the
tissue damage from MI, is responsible for the suppression of SDF-1a
release. Transmyocardial gradient = coronary sinus level - coronary
artery level; stable = stable coronary artery disease; UAP = unstable
angina pectoris; MI = myocardial infarction.
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cance for the progression of all translational research
from murine studies.
Several authors have described different findings from
ours; in particular, they have described increased SDF1a
expression following MI [2,4,5]. However, we believe
that this may be due to differences in strain of mouse
used (CD1 mice in [2]) or species studied (rats in [4,5]).
In contrast, we used C57Bl6 mice in our studies and
found a decrease in RNA and protein expression.
Figure 3 MCP-1 expression in the murine heart. Increased expression of mRNA for MCP1 (A) and its cognate receptor CCL2 (B) in the murine
heart following myocardial infarction occurs early, then returns to near baseline levels after 28 days. (C) MCP-1 protein levels are not statistically
significantly different following MI. IZ = infarct zone; BZ = border zone of the infarct; RZ = remote zone.
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weight to our conclusions that interspecies variations
are significant, and that observational translational clini-
cal trials are paramount before progressing to clinical
trials of therapies based on rodent data.
SDF-1a has been shown to be chemoattractant for
stem cells [2,4,23], pro-angiogenic [24] and anti-apopto-
tic for cardiac myocytes [25]. Whilst the stem cell che-
motactic properties capture the imagination, the absence
of release of SDF-1a from the human heart suggest that
this may not be its primary mechanism of action follow-
ing MI. Confounding the issue, and further emphasizing
the difference between rodent models and man, is the
presence of coronary artery disease in humans. The sup-
pression of SDF-1a release from the heart in both stable
and unstable coronary artery syndromes suggests that
coronary artery disease itself reduces the release of SDF-
1a. Perhaps the coronary artery plaques themselves
sequester SDF-1a from the circulation. The mechanism
of SDF-1a inducing cardiac repair remains incompletely
understood, but our data demonstrates that in humans,
SDF-1a release from the heart is reduced after MI.
Some prior observational studies have shown increased
peripheral blood levels of SDF-1a after MI [8,9] but our
data would suggest that if elevated levels of SDF-1a are
detected in peripheral blood, it originates from tissues
other than the heart.
It is not known whether the reduction in cytokine
release of SDF-1a and MCP-1 are beneficial or
detrimental to the LV remodeling process. In the case
of SDF-1a, we and others [1,7] have shown that there is
reduced myocardial SDF-1a production, and there is
experimental evidence that myocardial delivery of SDF-
1a can repair damaged myocardium [25]. With our
human data mimicking the murine data, it would be
reasonable to speculate that SDF-1a delivery to damaged
human myocardium would result in improved LV func-
tion. However, with respect to MCP-1, quite the oppo-
site is true. Elevated levels of MCP-1 have been
demonstrated in peripheral blood following MI [18-20]
and higher levels correlate with poorer prognosis [21].
The animal model shows increased MCP-1 RNA in the
hearts of rodents subjected to MI, and one might logi-
cally speculate that the elevated peripheral blood level of
MCP-1 in humans after MI is produced by, and released
from, the damaged heart tissue. A knockout animal
Figure 4 MCP-1 release from the human heart. In humans, MCP-
1 is constitutively released from hearts with normal coronary
arteries. However, following myocardial infarction, myocardial release
of MCP-1 is reduced. This is the opposite pattern suggested from
the murine mRNA studies. Furthermore, MCP-1 release is suppressed
in all stages of coronary artery disease, suggesting that coronary
artery disease, rather than the tissue damage from MI, is responsible
for the suppression of MCP-1 release. Transmyocardial gradient =
coronary sinus level - coronary artery level; stable = stable coronary
artery disease; UAP = unstable angina pectoris; MI = myocardial
infarction.
Figure 5 Timescale of cytokine release following MI. There is no
correlation between the trans-myocardial gradient of SDF-1a (A) or
MCP-1 (B) with the time from infarction. R = Pearson’s correlation
co-efficient.
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cial effect on post-infarction LV remodeling [26]. Extra-
polating from all this, one might expect a strategy of
MCP-1 antagonism after MI to be therapeutically effec-
tive. However, our data shows that there is no increased
release of MCP-1 from the human heart following MI,
in fact there is a decrease. Therefore, it would likely not
be appropriate to pursue blockade of myocardial MCP-1
based on our current results. This underscores the
importance of human observational clinical studies to
ensure that the animal model is actually reflective of the
human disease. Performing this step in the advancement
from the bench to the bedside will prevent costly studies
that, although reasonable based on animal study data,
are unlikely to succeed based on the human data. This
will avoid exposing patients to unnecessary risk and
may save considerable amounts for ever-shrinking
research budgets.
For all who study animal models of human disease, it
is imperative to acknowledge that all models have lim-
itations. While it is easy and relatively inexpensive to
perform quantitative studies on murine cardiac mRNA,
it is comparatively difficult and expensive to perform
such studies on human cardiac tissue. Furthermore,
there are ethical and logistic difficulties in procuring
human heart samples. Thus, we frequently presume that
the murine findings will apply to the human situation;
our results suggest that this may not be the case. A lim-
itation to our study is that we have not directly com-
pared human mRNA to murine mRNA. This is because
of the aforementioned difficulties in procuring human
heart tissue. We also did not directly compare the trans-
myocardial release of these cytokines between species,
b e c a u s et h ec o r o n a r ys i n u si nt h em o u s ei ss i m p l yt o o
small to access. We therefore chose the most appropri-
ate available samples to compare between species, but
our results should be interpreted with these limitations
in mind. Another limitation of our study is that there
were more males in the 3 coronary artery disease groups
than in the normal control group (which is reflective of
coronary artery disease’s predilection for male subjects);
therefore we cannot exclude gender differences as play-
ing a small role in the differences between groups. How-
ever, we used all male mice in the murine study and
showed similar response to MI with SDF-1a, but differ-
ent response with MCP-1. This suggests that gender dif-
ferences are less likely to have confounded our clinical
results, but we cannot fully exclude the possibility of a
gender effect in cytokine release profiles. This possibility
warrants further study.
Conclusions
Release of SDF-1a from the heart into the circulation
following MI is suppressed in humans, and this is simi-
lar to the murine model. Release of MCP-1 is also sup-
p r e s s e d ,b u tt h i si si nd i r e c tc o n t r a - d i s t i n c t i o nt ot h e
murine model. Observational clinical studies like this
are important to confirm whether the human disease
state is accurately reflected by the animal model, and to
guide future therapeutic strategies.
List of Abbreviations Used
SDF-1a: Stromal-derived factor 1-alpha; MCP-1: Monocyte chemotactic
protein 1; CCR2: C-C chemokine receptor 2; CXCR4: CXC chemokine receptor
4; MI: myocardial infarction; LV: left ventricle; KCl: potassium chloride; mRNA:
messenger ribonucleic acid.
Table 2 Patient demographics
Normal Stable CAD Unstable Angina MI
n=4 n=1 5 n=6 n=2 1
Male* n (%) 1 (25%) 10 (67%) 5 (83%) 19 (90%)
Age (years) Mean +/- s.d 65 +/- 0.5 70 +/- 8.1 58 +/- 11 61 +/- 12
Cardiovascular Risk Factors
Diabetes Mellitus n (%) 2 (50%) 6 (40%) 1 (17%) 11 (52%)
Hypertension n (%) 4 (100%) 12 (80%) 3 (50%) 13 (62%)
Dyslipidemia n (%) 2 (50%) 12 (80%) 4 (67%) 16 (76%)
Family Hx n (%) 0 (0%) 11 (73%) 4 (67%) 12 (57%)
Smoking Hx n (%) 1 (25%) 7 (47%) 4 (67%) 15 (71%)
Medications
Nitroglycerin n (%) 1 (25%) 5 (33%) 4 (67%) 7 (33%)
Statin n (%) 1 (25%) 7 (47%) 3 (50%) 14 (67%)
ACEI/ARB n (%) 2 (50%) 8 (53%) 2 (33%) 12 (57%)
Beta Blocker n (%) 1 (25%) 6 (40%) 5 (83%) 13 (62%)
Aspirin n (%) 2 (50%) 9 (60%) 3 (50%) 16 (76%)
*p < 0.05. CAD = coronary artery disease; MI = myocardial infarction; Hx = history; ACEI = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor
blocker.
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